Jefferies upgraded PeptiDream to Buy from Hold with a price target of 1,600 yen, down from 1,900 yen. The analyst says the company seems likely to book a strong Q3 on the back of milestone and upfront payments from Merck, Astellas and Genentech.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>